Cybin Inc N.CYBN

Alternate Symbol(s): CYBN

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

NEO:CYBN - Post by User

Cybin Inc

Bullboard Posts

Post by realitycheck00on Nov 25, 2020 8:18pm

815 Views

Post# 31975660

Cybin CEO Track record

More concerened about the track record of the CEO who has over $4B in exits and Billions raised and $400m to $1B+ in revenue generation across the pharma sector. I know that cannabis story and just like 90% of the other cannabis companies that fell flat its no different. Also he is an advisor so whats your point. You judge a company based on 1 advisor?

Bullboard Posts

Global Tungsten Market and Supply Security